ArticleIndian journal of ophthalmology2018
Clinical features and treatment outcomes of vasoproliferative tumors in Indian participants.
Article in Indian journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 21 citations in OpenAlex.
- Vasoproliferative Tumors of the Retina: Pathophysiology, Clinical Features, and Treatment Approaches.Ocular oncology and pathology · 2026Article
- A case of primary vasoproliferative tumor with full-thickness macular hole.GMS ophthalmology cases · 2022Article
- Macular sequelae in vasoproliferative tumors: results of surgical approach.International ophthalmology · 2021Article
- Retinal vasoproliferative tumor - A proposal for classification.Indian journal of ophthalmology · 2018Article
- Retinal vasoproliferative tumor regression after intravitreal aflibercept.Taiwan journal of ophthalmologyArticle
- Large Vasoproliferative Retinal Tumor Refractory to Cryotherapy Treated with Salvage I-125 Plaque Radiation Therapy.Advances in radiation oncologyArticle
- Vasoproliferative Retinal Tumors: Manifestations, Management, and Outcomes in a Case Series.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the study was to describe the clinical features and treatment outcomes of vasoproliferative tumors (VPT) in Indian participants.
methodsThis study design was a retrospective case series in a tertiary eye care center. Case records of patients diagnosed with VPT from 2011 to 2015 were reviewed, and their demographic details, clinical presentation, and treatment outcomes were documented. Baseline and follow-up visual acuity and tumor dimensions were statistically compared by applying paired t-test. Statistical analysis used SPSS version 14.
resultsTwenty-two tumors from 19 eyes of 17 patients were included. Mean age at presentation was 43.5 years (range: 15-68 years). Mean presenting best-corrected visual acuity (BCVA) was + 1.10 logMAR. Sixty-eight percent eyes had secondary tumors. Most common association of secondary VPT was Coats disease followed by retinal vasculitis, polypoidal choroidal vasculopathy, familial exudative vitreoretinopathy, and traumatic chorioretinopathy. Ten tumors (45%) involved the inferior quadrant. Tumor-associated features were intra/subretinal exudates, vitritis, subretinal fluid, vitreous hemorrhage, preretinal fibrosis, epiretinal membrane, and subretinal blood. Treatment included cryotherapy, intravitreal or oral steroids, laser photocoagulation, cryotherapy with encirclage, cryotherapy with anti-vascular endothelial growth factor, and observation. Complications included tumor recurrence, retinal detachment, raised intraocular pressure, neovascularization of iris, and cataract. Ninety-five percent VPT regressed at mean 21 months (Median: 17 months; Range: 3-64 months). Mean final BCVA was + 1.21 logMAR.
conclusionVPTs are commonly unilateral, unifocal, and located anterior to equator in inferior fundus. Secondary tumors are more common than primary tumors. Treatment achieves tumor regression in majority of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.